Anagliptin-Induced Vasorelaxation via Kv Channel and SERCA A
2026-07-20
A recent study demonstrates that Anagliptin (SK-0403) induces vasorelaxation in rabbit aortic smooth muscle by selectively activating voltage-dependent K+ (Kv) channels and the SERCA pump, independent of endothelium or classical cyclic nucleotide signaling. These findings expand Anagliptin’s research relevance beyond glycemic control, offering mechanistic insight into vascular tone regulation in diabetes models.
Propranolol Reverses Burn-Induced Metabolic Dysregulation
2026-07-19
This phase II trial demonstrates that propranolol, a non-selective β-adrenergic receptor blocker, significantly normalizes metabolic and lipidomic signatures in severely burned patients, leading to improved clinical outcomes. The findings clarify propranolol's mechanistic role in attenuating hypermetabolism and inflammation post-burn, offering new translational insights for metabolic modulation in critical care.
AM 281: CB1 Cannabinoid Receptor Antagonist for Neuropharmac
2026-07-18
AM 281, a highly selective CB1 cannabinoid receptor antagonist from APExBIO, enables advanced modeling of glutamate excitotoxicity and cognitive dysfunction in traumatic brain injury (TBI) and addiction research. By precisely inhibiting CB1 signaling, AM 281 empowers reproducible manipulation of neuroprotective pathways, as demonstrated in recent studies.
Trelagliptin Succinate in Type 2 Diabetes and Bone Research
2026-07-17
Trelagliptin succinate (SYR-472 succinate) stands out as a once-weekly, long-acting DPP-4 inhibitor, offering both glycemic control and novel benefits in bone and cognitive research. This article explores hands-on workflows, data-driven protocols, and troubleshooting strategies, uniquely bridging diabetes mellitus research with osteogenesis and neuroprotection.
Trelagliptin Succinate Workflows for Advanced Diabetes Resea
2026-07-17
Trelagliptin succinate (SYR-472 succinate) empowers type 2 diabetes research with once-weekly DPP-4 inhibition, robust pathway modulation, and proven efficacy in insulin resistance models. This guide distills applied workflows, protocol optimizations, and troubleshooting insights to maximize translational data quality using APExBIO’s high-purity reagent.
Trelagliptin Succinate: Mechanisms and Benchmarks in T2DM Re
2026-07-16
Trelagliptin succinate is a selective, long-acting DPP-4 inhibitor used primarily in type 2 diabetes research. It demonstrates potent glucose-lowering effects, robust selectivity, and favorable pharmacological properties, with evidence supporting efficacy and analytical quality control. This article details its mechanism, evidence base, and workflow integration.
Trelagliptin Succinate Improves Insulin Resistance in Adipoc
2026-07-16
The referenced study elucidates how Trelagliptin succinate, a DPP-4 inhibitor, improves insulin resistance in adipocytes via upregulation of the PI-3K/AKT/GLUT4 pathway. These findings clarify the molecular basis for its glucose-lowering effects and suggest broader relevance for diabetes mellitus research.
Nicotine’s Role in Chronic Kidney Disease Progression: Mecha
2026-07-15
This article examines how nicotine signaling accelerates chronic kidney disease (CKD) progression, focusing on the activation of renal nicotinic acetylcholine receptors and the induction of oxidative stress and fibrotic pathways. The study’s findings highlight mechanistic targets for intervention and underscore the importance of antioxidant bioactive compounds in CKD research.
Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding
2026-07-15
The reference study uncovers that naturally occurring angiotensin peptides, particularly truncated forms such as Angiotensin 1/2 (5-7), significantly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings redefine the intersection of renin-angiotensin system biology and COVID-19 pathogenesis, highlighting new avenues for both cardiovascular and viral research.
Streptavidin-Cy3 in Next-Gen Biotin Detection and Biohybrid
2026-07-14
Explore the advanced roles of Streptavidin-Cy3 in high-resolution biotin detection and its unique implications for biohybrid microrobots and adaptive imaging. This article offers a deeper look at assay optimization and the latest innovations beyond conventional applications.
Cell Counting Kit-8: Sensitive Cell Proliferation & Viabilit
2026-07-14
Cell Counting Kit-8 (CCK-8) from APExBIO delivers highly sensitive, reproducible cell proliferation and cytotoxicity measurements with a user-friendly workflow for modern biomedical research. Explore workflow enhancements, troubleshooting insights, and practical integration with cartilage regeneration and OA intervention studies.
ML216, BLM Helicase Inhibitor: Precision Tools for DNA Repai
2026-07-13
ML216, a potent BLM helicase inhibitor from APExBIO, enables researchers to dissect DNA repair vulnerabilities and model synthetic lethality with exceptional selectivity and submicromolar potency. This article delivers actionable workflows, troubleshooting strategies, and translational perspectives for maximizing ML216’s impact in cancer biology.
GSK343: Precision EZH2 Inhibitor for Epigenetic Cancer Resea
2026-07-13
GSK343 stands out as a potent, selective EZH2 inhibitor empowering researchers to dissect histone H3K27 trimethylation and its impact on tumor immunogenicity. This guide delivers actionable protocols, troubleshooting strategies, and workflow enhancements for leveraging GSK343 in breast and prostate cancer research.
Phenothiazines Induce Macrophage ROS and Autophagy for Antib
2026-07-12
This study demonstrates that phenothiazines significantly boost the antibacterial function of macrophages by triggering reactive oxygen species (ROS) and autophagy. These findings highlight a promising host-directed therapeutic strategy to combat intracellular bacterial infections, especially in the context of increasing antimicrobial resistance.
Novel PDK4 Inhibitors: Advancing Metabolic Disease Therapeut
2026-07-10
This article reviews a recent study identifying allosteric PDK4 inhibitors with strong in vitro and in vivo activity, particularly compound 8c, which improved glucose tolerance and suppressed allergic and cancer-related processes. The findings highlight new molecular scaffolds for metabolic disease drug development and underscore the importance of precise kinase modulation in translational research.
468 records 12/32 page Previous Next First page 上5页 1112131415 下5页 Last page